OPKO Health, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing share count, ongoing product activity, and a pending laboratory business sale to Labcorp.
Key Highlights
- Shares outstanding: As of October 20, 2026, the registrant had 742,506,477 shares of Common Stock outstanding, according to the filing.
- Pending Labcorp transaction: The filing identifies as a risk factor "our ability to complete the sale of BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections and certain operational assets to Labcorp."
- Key products referenced: The filing names NGENLA (Somatrogon) and Rayaldee among pharmaceutical and collaboration arrangements from which the company may or may not generate substantial revenue.
- ModeX Therapeutics pipeline: The filing lists as a risk whether "the products in the ModeX Therapeutics, Inc. R&D pipeline will ultimately be commercialized."
- Corporate Integrity Agreement: The filing cites the company's "2022 Corporate Integrity Agreement with the U.S. Office of Inspector General of the Department of Health and Human Services" as an ongoing compliance obligation.
- Accelerated filer status: The registrant is classified as an accelerated filer, not a large accelerated filer, smaller reporting company, or emerging growth company.
OPKO Health's Third-Quarter 2026 Filing: Key Disclosures on Operations and Pending Asset Sale
OPKO Health, Inc. (NASDAQ:OPK), headquartered at 4400 Biscayne Blvd., Miami, FL 33137, filed its Form 10-Q for the quarterly period ended September 30, 2026 on November 4, 2026. The filing confirms that as of October 20, 2026, the company had 742,506,477 shares of Common Stock outstanding. The company is classified as an accelerated filer under Rule 12b-2 of the Exchange Act.
Among the notable disclosures, the filing flags the pending sale of BioReference Health's laboratory testing businesses to Labcorp as a risk factor, citing uncertainty around "satisfying closing conditions, obtaining required regulatory approvals, and realizing the anticipated benefits of the transaction." The filing also notes risks tied to the company's ability "to successfully manage the transition services to be provided following the closing of the Labcorp transaction and the separation of the diagnostic operations." No closing date or financial terms for the Labcorp transaction are specified in the portion of the filing provided.
The filing references NGENLA (Somatrogon) and Rayaldee as products from which the company may or may not generate substantial revenue, and identifies the ModeX Therapeutics, Inc. R&D pipeline as subject to commercialization uncertainty. The company also discloses an ongoing compliance obligation under its 2022 Corporate Integrity Agreement with the U.S. Office of Inspector General of the Department of Health and Human Services. The filing contains forward-looking statements that, according to the company's own cautionary language, are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
What Was Disclosed
OPKO Health filed its September 30, 2026 quarterly report disclosing 742,506,477 shares outstanding, a pending BioReference Health asset sale to Labcorp, referenced pharmaceutical products, ModeX Therapeutics pipeline risks, and an active 2022 Corporate Integrity Agreement.



Please wait processing your request...